• InfuSystem outlined a home healthcare platform for complex therapies outside hospitals, combining reimbursement support, logistics, and 24/7 clinical services.
• For FY 2025, net revenue USD 143.4 million; adjusted EBITDA USD 31.5 million; adjusted EBITDA margin 21.9%; operating cash flow USD 24.4 million.
• Liquidity of USD 58.2 million positioned to fund growth initiatives, including selective tuck-in acquisitions.
• Patient Services about 60% of revenue at USD 86 million-plus; Device Solutions about 40% at USD 56 million-plus.
• Targeting sustained adjusted EBITDA margin of 22%-25%, supported by ERP cost roll-off and a shift toward less capital-intensive growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.